Wealth Enhancement Advisory Services
BLRX

Wealth Enhancement Advisory Services’s BioLineRX BLRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-263
Closed -$2.25K – 3003
2024
Q4 		$2.25K Hold
263
– – ﹤0.01% 2943
2024
Q3 		$5.63K Buy
+263
New +$7.22K ﹤0.01% 2745

Other funds holding BLRX

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wealth Enhancement Advisory Services's BLRX Position: Q1 2025 in Review

Wealth Enhancement Advisory Services sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 263 shares — an estimated $2.25K sold.

Wealth Enhancement Advisory Services first reported a position in BLRX in Q3 2024 and held it in 2 quarters. The position peaked at $5.63K in Q3 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • Wealth Enhancement Advisory Services reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 263 BioLineRX shares in Q1 2025, an estimated $2.25K.
  • Wealth Enhancement Advisory Services first reported a position in BioLineRX in Q3 2024 and held it in 2 quarters.
  • Wealth Enhancement Advisory Services's BioLineRX position peaked at $5.63K in Q3 2024.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2025, filed 16 Apr 2025.